Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India

Alter, 2006, Epidemiology of viral hepatitis and HIV co-infection, J Hepatol, 44, 6, 10.1016/j.jhep.2005.11.004 Colin, 1999, Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men, Hepatology, 29, 1306, 10.1002/hep.510290447 Konopnicki, 2005, Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort, AIDS, 19, 593, 10.1097/01.aids.0000163936.99401.fe Thio, 2003, Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment, Semin Liver Dis, 23, 125, 10.1055/s-2003-39951 Konopnicki, 2005, Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort, AIDS, 19, 2117, 10.1097/01.aids.0000163936.99401.fe Yu, 1997, Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers, Am J Epidemiol, 145, 1039, 10.1093/oxfordjournals.aje.a009060 Bodsworth, 1991, The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state, J Infect Dis, 163, 1138, 10.1093/infdis/163.5.1138 Gilson, 1997, Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection, AIDS, 11, 597, 10.1097/00002030-199705000-00007 Alberti, 2005, Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients, J Hepatol, 42, 615, 10.1016/j.jhep.2005.03.003 Ristig, 2002, Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-co-infected individuals for whom interferon-alpha and lamivudine therapy have failed, J Infect Dis, 186, 1844, 10.1086/345770 Benhamou, 2003, Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus, N Engl J Med, 348, 177, 10.1056/NEJM200301093480218 Bani-Sadr, 2004, Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients co-infected with HIV-1 and wild-type hepatitis B virus, Clin Infect Dis, 39, 1062, 10.1086/424012 Dore, 2004, Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients co-infected with HIV-1 and hepatitis B virus, J Infect Dis, 189, 1185, 10.1086/380398 Nelson, 2003, An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals, AIDS, 17, F7, 10.1097/00002030-200301030-00002 Benhamou, 2008, Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients, Hepatology, 48, 1062 Matthews, 2009, Combination HBV therapy is linked to greater HBV-DNA suppression in a cohort of lamivudine-experienced HIV/HBV co-infected individuals, AIDS, 23, 1707, 10.1097/QAD.0b013e32832b43f2 Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (accessed 22 August 2010). Matthews, 2008, A randomized trial of combination hepatitis B therapy in HIV/HBV co-infected antiretroviral naive individuals in Thailand, Hepatology, 48, 1062, 10.1002/hep.22462 Tankhiwale, 2003, Seroprevalence of anti HCV and hepatitis B surface antigen in HIV infected patients, Indian J Med Microbiol, 21, 268, 10.1016/S0255-0857(21)03012-7 Saravanan, 2007, Co-infection of hepatitis B and hepatitis C virus in HIV infected patients in South India, World J Gastroenterol, 13, 5015, 10.3748/wjg.v13.i37.5015 Kumarasamy, 2003, Natural history of human immunodeficiency virus disease in southern India, Clin Infect Dis, 36, 79, 10.1086/344756 Padmapriyadarsini, 2006, Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function, J Postgrad Med, 52, 92 Gupta, 2010, Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in North India, BMC Infect Dis, 10, 53, 10.1186/1471-2334-10-53 Law, 2004, Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort, AIDS, 18, 1169, 10.1097/00002030-200405210-00010 De Luca, 2002, Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects, Arch Intern Med, 162, 2125, 10.1001/archinte.162.18.2125 Sheng, 2004, Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic, Clin Infect Dis, 38, 1471, 10.1086/420744 Sheng, 2007, Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy, Clin Infect Dis, 45, 1221, 10.1086/522173 Liaw, 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056/NEJMoa033364 Chen CJ, Yang HI, Su J, Jen CL, Kuo E, You SL. Elevated serum level of hepatitis B virus DNA is an independent risk factor for hepatocellular carcinoma: a long-term follow-up study in Taiwan. In: 40th Annual Meeting of the European Association for the Study of the Liver. 13–17 April 2005; Paris, France. Zurich: EASL; 2005, Abstract 35. Chen CJ, Yang HI, Su J, Jen CL, Kuo E, You SL. Viral load is a strong predictor of liver cirrhosis risk in people chronically infected with hepatitis B virus regardless of hepatitis B e antigen status. In: 40th Annual Meeting of the European Association for the Study of the Liver. 13–17 April 2005; Paris, France. Zurich: EASL; 2005, Abstract 476. Bender, 2010, Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India, Clin Infect Dis, 50, 416, 10.1086/649884